F Morabito

Summary

Country: Italy

Publications

  1. ncbi request reprint Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil
    Fortunato Morabito
    Haematologica 87:217-8. 2002
  2. ncbi request reprint Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma
    Fortunato Morabito
    Centro Trapianti di Midollo Osseo, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Haematologica 87:1192-9. 2002
  3. doi request reprint Perspectives in the treatment of multiple myeloma
    Massimo Gentile
    Unità Operativa Complessa di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera di Cosenza, Viale della Repubblica, 87100 Cosenza, Italy
    Expert Opin Biol Ther 13:S1-22. 2013
  4. ncbi request reprint Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium
    Fortunato Morabito
    Unità Operativa Complessa di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera di Cosenza, Viale della Repubblica, 87100 Cosenza, Italy
    Curr Cancer Drug Targets 12:743-56. 2012
  5. doi request reprint Emerging biological insights and novel treatment strategies in multiple myeloma
    Massimo Gentile
    Unità Operativa Complessa di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera di Cosenza, Viale della Repubblica, 87100 Cosenza, Italy
    Expert Opin Emerg Drugs 17:407-38. 2012
  6. doi request reprint Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial
    Fortunato Morabito
    UOC di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera, Cosenza, Italy
    Leuk Lymphoma 53:406-10. 2012
  7. pmc The CD38 ectoenzyme family: advances in basic science and clinical practice
    Fortunato Morabito
    Unità Operativa di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy
    Mol Med 12:342-4. 2006
  8. ncbi request reprint Molecular indicators of prognosis in mantle cell lymphoma in the era of R-hyper-CVAD: still an open issue
    Fortunato Morabito
    Unità Operativa di Ematologia, Presidio Ospedaliero dell Annunziata, Azienda Ospedaliera, Cosenza, Italy
    Leuk Lymphoma 48:1461-2. 2007
  9. ncbi request reprint The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
    F Morabito
    Unità Operativa di Ematologia, Presidio Ospedaliero dell Annunziata, Azienda Ospedaliera, Cosenza, Italy
    Bone Marrow Transplant 37:283-8. 2006
  10. ncbi request reprint Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia
    Fortunato Morabito
    Unità Operativa Complessa di Ematologia, Azienda Ospedaliera, Cosenza, Italy
    Br J Haematol 146:44-53. 2009

Detail Information

Publications86

  1. ncbi request reprint Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil
    Fortunato Morabito
    Haematologica 87:217-8. 2002
    ....
  2. ncbi request reprint Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma
    Fortunato Morabito
    Centro Trapianti di Midollo Osseo, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Haematologica 87:1192-9. 2002
    ..Furthermore, there are considerable concerns regarding the appropriate use of health care resources in order to reduce costs associated with PBSCT. One of the strategies attempted to reach this goal is outpatient-based PBSCT...
  3. doi request reprint Perspectives in the treatment of multiple myeloma
    Massimo Gentile
    Unità Operativa Complessa di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera di Cosenza, Viale della Repubblica, 87100 Cosenza, Italy
    Expert Opin Biol Ther 13:S1-22. 2013
    ..Nevertheless, almost all patients show disease relapse and develop drug resistance...
  4. ncbi request reprint Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium
    Fortunato Morabito
    Unità Operativa Complessa di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera di Cosenza, Viale della Repubblica, 87100 Cosenza, Italy
    Curr Cancer Drug Targets 12:743-56. 2012
    ....
  5. doi request reprint Emerging biological insights and novel treatment strategies in multiple myeloma
    Massimo Gentile
    Unità Operativa Complessa di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera di Cosenza, Viale della Repubblica, 87100 Cosenza, Italy
    Expert Opin Emerg Drugs 17:407-38. 2012
    ..Nevertheless, almost all MM patients show disease relapse and develop drug resistance...
  6. doi request reprint Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial
    Fortunato Morabito
    UOC di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera, Cosenza, Italy
    Leuk Lymphoma 53:406-10. 2012
    ..In conclusion, the prognostic role of GST polymorphism, if at all, is limited to a small subgroup of patients treated with standard ABVD regimen...
  7. pmc The CD38 ectoenzyme family: advances in basic science and clinical practice
    Fortunato Morabito
    Unità Operativa di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy
    Mol Med 12:342-4. 2006
    ....
  8. ncbi request reprint Molecular indicators of prognosis in mantle cell lymphoma in the era of R-hyper-CVAD: still an open issue
    Fortunato Morabito
    Unità Operativa di Ematologia, Presidio Ospedaliero dell Annunziata, Azienda Ospedaliera, Cosenza, Italy
    Leuk Lymphoma 48:1461-2. 2007
  9. ncbi request reprint The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
    F Morabito
    Unità Operativa di Ematologia, Presidio Ospedaliero dell Annunziata, Azienda Ospedaliera, Cosenza, Italy
    Bone Marrow Transplant 37:283-8. 2006
    ..Finally, patients with a high-risk score had little chance of receiving potentially curative treatment...
  10. ncbi request reprint Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia
    Fortunato Morabito
    Unità Operativa Complessa di Ematologia, Azienda Ospedaliera, Cosenza, Italy
    Br J Haematol 146:44-53. 2009
    ..8, 95% confidence interval (CI) 2.4-5.8] and high-risk group (HR = 8.0, 95% CI 3.9-16.2). Specific transcriptional patterns were significantly associated with risk groups...
  11. doi request reprint Insights into defibrotide: an updated review
    F Morabito
    Unità Operativa Complessa di Ematologia, Dipartimento di Medicina Interna, Azienda Ospedaliera di Cosenza, Viale della Repubblica, Cosenza 87100, Italy
    Expert Opin Biol Ther 9:763-72. 2009
    ..Animal models have clearly shown the potential antineoplastic effect of this drug. Further clinical investigations are needed to clarify this new application...
  12. doi request reprint Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA
    Fortunato Morabito
    Unità Operativa di Ematologia, Azienda Ospedaliera dell Annunziata, 87100 Cosenza, Italy
    Eur J Haematol 84:223-8. 2010
    ..In conclusion, bortezomib-based regimens are safe and effective and should be considered as appropriate treatment options for MM patients with any degree of RI...
  13. doi request reprint Janus kinase 2 inhibitors in myeloproliferative disorders
    Eugenio Lucia
    Unità Operativa Complessa di Ematologia, Dipartimento di Medicina Interna, Azienda Ospedaliera di Cosenza, Viale della Repubblica, 87100 Cosenza, Italy
    Expert Opin Investig Drugs 20:41-59. 2011
    ....
  14. doi request reprint Epigenetic regulation in myelodysplastic syndromes: implications for therapy
    Ernesto Vigna
    Unità Operativa Complessa di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera di Cosenza, Viale della Repubblica, Cosenza, Italy
    Expert Opin Investig Drugs 20:465-93. 2011
    ..Growing evidence suggests that targeting epigenetic mechanisms improves MDS/AML pathophysiology...
  15. ncbi request reprint Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi
    Fortunato Morabito
    Centro Trapianti Midollo Osseo, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Cancer 101:1601-8. 2004
    ..To assess the impact of T-cell/B-cell phenotype on clinical outcome, the authors retrospectively compared patients who had peripheral T-cell lymphoma, unspecified (PTCL-U), with patients who had diffuse large B-cell lymphoma (DLBCL)...
  16. doi request reprint The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia
    Fortunato Morabito
    Onco Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy
    Blood 118:6353-61. 2011
    ..sFLC(κ + λ) assessment represents a sensitive and cost-effective tool for identifying CLL patients requiring early treatment...
  17. doi request reprint Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment
    Fortunato Morabito
    Unitá Operativa Complessa UOC Ematologia, Dipartimento Oncoematologico, A O di Cosenza, Cosenza, Italy
    Blood 118:5759-66. 2011
    ..VMPT-VT had no advantage in terms of RI reversal over VMP...
  18. doi request reprint Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs
    Fortunato Morabito
    Divisione di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy
    Eur J Haematol 85:181-91. 2010
    ..The most relevant articles on therapy of MM published from November 1982 to January 2010 (selected through PubMed), and recent meeting abstracts were used as sources for this review...
  19. ncbi request reprint Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy
    F Morabito
    Centro Trapianti di Midollo Osseo, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
    Bone Marrow Transplant 28:883-8. 2001
    ..In conclusion, MBC patients treated with a conditioning regimen containing only one alkylating agent and adequate prophylaxis for mucositis may qualify for outpatient-based PBSCT on the basis of a lower risk of infection...
  20. ncbi request reprint Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs
    F Morabito
    Dipartimento di Emato Oncologia, Azienda Ospedaliera Melacrino Bianchi Morelli, Reggio Calabria, Italy
    Haematologica 82:16-20. 1997
    ..p53 gene mutations have also been suggested to account for the chlorambucil resistance in CLL. Thus we studied the relationship between bcl-2 protein expression, p53 gene mutations and in vitro drug sensitivity in CLL...
  21. ncbi request reprint 'In vivo' time course of plasma myeloperoxidase levels after granulocyte colony-stimulating factor-induced stem cell mobilization
    F Morabito
    Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Transfus Med 15:425-8. 2005
    ..These findings may contribute to a better understanding of G-CSF safety profile in stem cell donors...
  22. ncbi request reprint Two consecutive courses of rh-G-CSF-mobilized peripheral blood stem cells for primary marrow alloengraftment failure: case report
    M Martino
    Centro Trapianti di Midollo Osseo e Terapie Onco Ematologiche Sovramassimali Alberto Neri, Dipartimento di Emato Oncologia, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Haematologica 81:464-7. 1996
    ..Therefore we suggest that growth factor-stimulated peripheral blood should be considered as the first choice for allogeneic stem cells in order to avoid primary graft failure with donors over 50 years of age...
  23. ncbi request reprint Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia
    F Morabito
    Centro Trapianti di Midollo Osseo, Dipartimento di Ematologia, Azienda Ospedaliera Bianchi Melacrino Morelli, 89100 Reggio, Calabria, Italy
    Leuk Res 25:927-32. 2001
    ..Multivariate analysis indicates that only the CD38 score successfully predicts survival (P=0.0028), with an estimated 3.8-fold greater risk of death for those cases with CD38 score >3...
  24. ncbi request reprint Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases
    C Stelitano
    Dipartimento di Emato Oncologia, Azienda Ospedaliera Bianchi Melacrino Morelli, 89100 Reggio Calabria, Italy
    Haematologica 84:317-23. 1999
    ..In order to contribute to clarifying the possible role of FAMP, we report a retrospective analysis of the results obtained with the purine analog in CLL patients in different phases of the disease...
  25. ncbi request reprint The CX3C chemokine fractalkine (CX3CL1) is detectable in serum of B cell chronic lymphocytic leukemia patients with lymph node involvement
    F Morabito
    Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Acta Haematol 113:152-4. 2005
  26. ncbi request reprint Clinical significance of HLA-DR+, CD19+, CD10+ immature B-cell phenotype and CD34+ cell detection in bone marrow lymphocytes from children affected with immune thrombocytopenic purpura
    V Callea
    Dipartimento di Emato Oncologia, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Haematologica 82:471-3. 1997
    ..No difference was found in the two groups of children in terms of age, presentation of the disease or final outcome. Finally, no patient in either children's group has developed an acute lymphoproliferative disorder...
  27. ncbi request reprint Basiliximab for the treatment of graft rejection in haploidentical peripheral blood stem cell transplantation
    G Messina
    Centro Trapianti di Midollo Osseo e Terapia Sovramassimali Emato Oncologiche Alberto Neri, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Haematologica 87:ECR44. 2002
  28. ncbi request reprint Retrospective analysis of mantle cell lymphoma: experience of the "Gruppo Italiano per lo Studio dei Linfomi" (GISL)
    V Callea
    Dipartimento di Emato Oncologia, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Haematologica 83:993-7. 1998
    ..Clinically, the reported unfavorable outcome of these patients has focused attention on this category of non-Hodgkin's lymphoma (NHL)...
  29. ncbi request reprint Surface CD14 positivity in B-cell chronic lymphocytic leukaemia is related to clinical outcome
    V Callea
    Dipartimento Emato Oncologia, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Br J Haematol 107:347-52. 1999
    ..8. In conclusion, these data reveal that CD14+ represents an important marker for predicting OS in B-CLL patients and, therefore, we suggest that it should be included in the immunological characterization of B-CLL...
  30. ncbi request reprint CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy
    F Ferrara
    Divisione di Ematologia, Sezione TERE, Servizio di Immunoematologia, Ospedale Cardarelli, Naples, Italy
    J Clin Oncol 18:1295-300. 2000
    ..We investigated the prognostic relevance of CD56 in a series of patients with APL who were treated homogeneously with all-trans-retinoic acid (ATRA) and chemotherapy...
  31. ncbi request reprint Harvesting peripheral blood progenitor cells from healthy donors with a short course of recombinant human granulocyte-colony-stimulating factor
    M Martino
    The Bone Marrow Transplantation Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Transfus Med 15:323-8. 2005
    ..The day 5 schedule allowed a more consistent achievement of the target cell dose with one leukapheresis (P = 0.005) and resulted in the initial collection of a significantly larger number of CD34+ cells (P = 0.006)...
  32. ncbi request reprint Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission
    F Ferrara
    Divisione di Ematologia, Ospedale Cardarelli, Napoli, Italy
    Haematologica 86:814-20. 2001
    ....
  33. ncbi request reprint Immunologic and molecular evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical remission phase
    M Brugiatelli
    Divisione di Ematologia, Ospedali Riuniti di Reggio Calabria Torino, Italy
    Cancer 63:1979-84. 1989
    ..Nonetheless, the follow-up of B-CLL patients by conventional immunologic markers may be helpful to better define response to therapy and to predict the occurrence of clinical relapse...
  34. doi request reprint Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients
    E Vigna
    Unità Operativa Complessa di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy
    Transpl Infect Dis 12:428-31. 2010
    ..We present 2 cases of transplanted patients affected by visceral leishmaniasis treated successfully with L-AMB...
  35. ncbi request reprint In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia
    F Morabito
    Hematology Oncology Department, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Eur J Haematol 58:301-6. 1997
    ..On the other hand, a more elevated number of antagonistic interactions were counted at CLB 100 micrograms/ ml. In conclusion, both DFZ and PDN synergize in vitro with CLB, especially at low concentrations of the alkylating agent...
  36. pmc Lipid peroxidation and protein oxidation in patients affected by Hodgkin's lymphoma
    F Morabito
    Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Mediators Inflamm 13:381-3. 2004
    ..These findings may contribute to a better definition of the redox homoeostasis dysregulation in HL...
  37. ncbi request reprint Diagnostic and prognostic relevance of the immunophenotype in acute myelocytic leukemia
    V Callea
    Divisione di Ematologia, Ospedali Riuniti, Reggio Calabria, Italy
    Tumori 77:28-31. 1991
    ..These findings indicate that immunophenotype may identify some FAB subtypes. Moreover, in some cases the phenotypic profile can provide useful information about the clinical outcome...
  38. ncbi request reprint Differences in transplant-related complications between hematologic malignancies and solid tumors receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantation
    Massimo Martino
    Centro Trapianti Midollo Osseo A Neri, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Tumori 89:385-90. 2003
    ..Transplant-related mortality was similar between the two groups. In conclusion, patients with a hematological malignancy overall have more complications than those with a solid tumor...
  39. ncbi request reprint Eosinophilic fasciitis associated with autoimmune phenomena after bone marrow transplantation: report of two cases
    Paola L Minciullo
    Department of Human Pathology, School of Allergy and Clinical Immunology, University of Messina, Via Consolare Valeria, 98125 Messina, Italy
    Clin Rheumatol 25:80-2. 2006
    ..Moreover, we report for the first time the association of fasciitis with autoimmune phenomena after BMT. The correlation between the two entities is supported by remission of Hashimoto's thyroiditis after ECP treatment for fasciitis...
  40. ncbi request reprint Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy
    Vincenzo Callea
    Hematology Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Leuk Lymphoma 47:2314-20. 2006
    ..In conclusion, SN development is dependent on the length of follow-up rather than on therapy duration. F + C should be administered with caution after prolonged CLB therapy...
  41. ncbi request reprint Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim
    Massimo Martino
    Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    J Clin Apher 20:129-36. 2005
    ..No donor in either group developed long-term adverse effects. We conclude that both G-CSFs are comparable in terms of CD34+ cell collection, safety and tolerability...
  42. ncbi request reprint First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective
    Pellegrino Musto
    Unit of Hematology and Stem Cell Transplantation, IRCCS CROB, Centro di Riferimento Oncologico, della Basilicata, Rionero in Vulture PZ, Italy
    Curr Drug Targets 10:906-22. 2009
    ..We also assess the role of autologous and allogeneic stem-cell transplantation with adjusted conditioning regimens in selected elderly patients...
  43. ncbi request reprint High-dose chemotherapy with mitoxantrone + melphalan and autologous stem cell rescue in metastatic breast cancer patients: a study of feasibility and tolerability
    Massimo Martino
    Centro Trapianti Midollo Osseo, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Tumori 89:492-6. 2003
    ..9% after the treatment with mitoxantrone-melphalan. We conclude that a conditioning regimen with high dose mitoxantrone-melphalan fits well within the high-dose chemotherapy program...
  44. ncbi request reprint High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients
    Massimo Martino
    Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Am J Hematol 81:973-8. 2006
    ..In conclusion, an up-front tandem strategy with a very low reduced intensity-conditioning regimen for allografting following autografting is feasible and induces high CR/nCR rate in MM...
  45. ncbi request reprint Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients
    Massimo Martino
    Department of Bone Marrow Transplant, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Eur J Haematol 78:35-40. 2007
    ..1% to 76.5%). In conclusion, Thal as maintenance therapy after double ASCT is associated with low feasibility and high toxicity and could prevent a lengthy use of this antineoplastic agent...
  46. pmc Rituximab for the treatment of patients with chronic lymphocytic leukemia
    M Gentile
    UOC di Ematologia, Azienda Ospedaliera di Cosenza, Italy
    Cancer Manag Res 2:71-81. 2010
    ....
  47. ncbi request reprint Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro
    Fortunato Morabito
    Dipartimento di Ematologia Azienda, Ospedaliera Bianchi Melacrino, Reggio Calabria, Italy
    Haematologica 88:864-73. 2003
    ..The aim of this study was to ascertain whether B-CLL cells, induced into apoptosis, expressed surface CD10, since a correlation between apoptosis and CD10 expression has been demonstrated...
  48. ncbi request reprint Non-Hodgkin's lymphoma associated with sickle cell disease: a case report
    F Morabito
    Divisione di Ematologia, Ospedali Riuniti Melacrino e Bianchi, Reggio Calabria
    Tumori 73:523-4. 1987
    ..This association has not been previously described. A correlation between the malignancy and the hemoglobinopathy could not be etiologically ascertained; therefore, an alternative explanation to a chance event cannot be offered...
  49. ncbi request reprint Hyperhomocysteinemia is associated with cognitive impairment in multiple sclerosis
    C Russo
    Neurologic Unit, Azienda Ospedaliera, Bianchi Melacrino Morelli, Reggio Calabria, Italy
    J Neurol 255:64-9. 2008
    ..262, p = 0.01). We conclude that tHcy levels are increased in MS and that HHcy is associated with cognitive impairment in this disease...
  50. ncbi request reprint Bone marrow failure associated with herpesvirus 8 infection in a patient undergoing autologous peripheral blood stem cell transplantation
    Maria Cuzzola
    Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Clin Infect Dis 37:e102-6. 2003
    ..Bone marrow failure was resistant to antiviral treatment and a second infusion of autologous stem cells. Human herpesvirus 8 infection continues to be a major concern in transplant recipients in critical condition...
  51. ncbi request reprint Systemic aspergillosis in a patient with non-Hodgkin's lymphoma developing acute graft-versus-host disease after autologous peripheral blood stem cell transplantation
    G Messina
    Centro Trapianti di Midollo Osseo e Terapia Sovramassimali Emato Oncologiche Alberto Neri, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Haematologica 87:ECR22. 2002
    ..Because of the immunosuppressive therapies, he developed systemic aspergillosis. He died in haematological complete remission despite infection-oriented treatment...
  52. pmc CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALL
    G Cutrona
    Servizi di Immunologia Clinica, Istituto Nazionale per la Ricerca sul Cancro, IST, Genoa, Italy, and Dipartimento di Oncologia, Biologia e Genetica, Universita di Genova, Genoa, Italy
    Br J Cancer 86:1776-85. 2002
    ....
  53. ncbi request reprint Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient
    Massimo Gentile
    Hematology Unit, Dipartimento di Medicina Interna, Azienda Ospedaliera di Cosenza, Via Migliori, 87100, Cosenza, Italy
    Cancer Chemother Pharmacol 62:741-3. 2008
    ..Here, we report the safety and efficacy of a rituximab-containing regimen in a CLL patient with steroid- and IVIg-refractory AIHA...
  54. doi request reprint The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods
    Eugenio Lucia
    Unità Operativa di Ematologia, Azienda Ospedaliera, Cosenza, Italy
    Leuk Lymphoma 49:1907-15. 2008
    ....
  55. doi request reprint Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion
    Esther N Oliva
    Hematology Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Eur J Haematol 85:231-5. 2010
    ..Lenalidomide elicits high response rates and morphological improvements in myelodysplastic syndrome (MDS) patients with chromosome 5q deletion [del(5q)]...
  56. ncbi request reprint Modification of the content of plasma protein carbonyl groups in donors after granulocyte colony stimulating factor-induced stem cell mobilization
    Fortunato Morabito
    Bone Marrow Transplant Unit, Azienda Ospedaliera, Bianchi Melacrino Morelli, 89100 Reggio Calabria, Italy
    Transfus Apher Sci 33:141-6. 2005
    ..These findings may contribute to better understand the oxidative reactions following rHuG-CSF treatment and leukapheresis...
  57. ncbi request reprint PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment
    Ernesto Vigna
    Unità Operativa di Ematologia Medicine, Cosenza, Italy
    Cancer Chemother Pharmacol 61:713-6. 2008
    ..We herein report a case of F/P-positive CEL with retro-orbital localization, who was successfully treated with imatinib...
  58. ncbi request reprint Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients
    Sara Galimberti
    Department of Oncology, Transplant and Advances in Medicine, Section of Haematology, University of Pisa, Italy
    Br J Haematol 120:405-12. 2003
    ..Thus, the failure of a predictive role for this highly sensitive molecular method could be explained by the assumption that in vivo persisting malignant cells are the true source of relapse in MM...
  59. doi request reprint Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study
    Stefano Sacchi
    Dipartimento di Oncologia ed Ematologia, Università di Modena Centro Oncologico Modenese Policlinico, 41100 Modena, Italy
    Haematologica 93:398-404. 2008
    ..The aim of this long-term follow-up study was to determine the incidence, the time free of second tumors, and risk factors for developing secondary cancer in a homogeneous group of patients with non-Hodgkin's lymphoma...
  60. ncbi request reprint Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)
    Marco Lombardo
    Dipartimento di Oncologia, Azienda Ospedaliera Santo Spirito, Pescara, Italy
    Leuk Lymphoma 43:1795-801. 2002
    ..In particular the BACOP schedule is a valid anthracycline-containing regimen, and in this respect suitable to be considered as a treatment option...
  61. ncbi request reprint Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms
    Valentina Maggini
    Department of Biology, Pisa University, Pisa, Italy
    Leuk Res 32:49-53. 2008
    ..60; 95% CI, 1.2-16.9, p=0.02). Pre-therapeutic individual determination of the GSTP1 and TYMS polymorphisms could help in choosing the most appropriate protocol...
  62. ncbi request reprint MDR1 polymorphism influences the outcome of multiple myeloma patients
    Gabriele Buda
    Department of Oncology, Transplants and Advanced Technologies, Section of Hematology, Pisa University, Pisa, Italy
    Br J Haematol 137:454-6. 2007
    ..Our data suggested a longer OS for patients with C/T and T/T genotypes (log-rank test, P = 0.02) compared with patients with C/C genotype...
  63. ncbi request reprint Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients
    Sara Galimberti
    Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S Chiara, Via Roma, 56 56100 Pisa, Italy
    Leuk Res 28:367-72. 2004
    ..8% of cases at high expression. A significant correlation between BCRP and MDR1 values was found by regression analysis. Either levels of BCRP or MDR1 did not correlate with clinical characteristics of patients at diagnosis...
  64. ncbi request reprint Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients
    Massimo Martino
    Bone Marrow Transplantation Unit, Azienda Ospedaliera Bianchi Melacrino Morelli, 89100, Reggio, Calabria, Italy
    Support Care Cancer 13:182-7. 2005
    ..008). Independently of Hb levels at PBSCT, rHuEPO therapy was significantly associated with a lower risk of transfusion requirement. In conclusion, rHuEPO is shown to be effective when administered prior to high-dose therapy in MM...
  65. ncbi request reprint Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation
    Sara Galimberti
    Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S Chiara Via Roma, 56 56100 Pisa, Italy
    Leuk Res 29:961-6. 2005
    ..01). These data sustain the relevant role of molecular monitoring in MM patients undergoing NMT. MRD monitoring would assist physicians in making additional therapeutic decisions to better control this hematological malignancy...
  66. ncbi request reprint FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia
    Sara Galimberti
    Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Italy
    Anticancer Res 23:3419-26. 2003
    ..A worse outcome for patients carrying FLT3 mutations or expressing MDR1 gene has been reported. This study was designed to verify the possible co-expression of mutated-FLT3 and MDR1 genes and to evaluate their independent prognostic role...
  67. ncbi request reprint Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation
    Sara Galimberti
    Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S Chiara, Via Roma, 56, 56100 Pisa, Italy
    Leuk Res 30:529-35. 2006
    ..These results suggest that different T gamma/delta populations would sustain GVM and GVH effects after non-myeloablative allogeneic transplant...
  68. ncbi request reprint CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells
    Silvia Deaglio
    Laboratory of Immunogenetics, Department of Genetics, Biology and Biochemistry, Via Santena 19, 10126 Turin, Italy
    Blood 102:2146-55. 2003
    ..Finally, CD38 signaling in IL-2-treated B-CLL cells prolonged survival and induced the appearance of plasmablasts, providing a pathogenetic hypothesis for the occurrence of Richter syndrome...
  69. ncbi request reprint Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera AO S Giovanni Battista, Turin, Italy
    Blood 109:2767-72. 2007
    ..Initial results showed that VMPT is an effective salvage therapy with a very high proportion of responses. The incidence of neurotoxicities was unexpectedly low...
  70. ncbi request reprint Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi
    Luca Baldini
    Unità Operativa Ematologia 1, Centro G Marcora, Ospedale Maggiore, IRCCS, Via F Sforza 35, 20121 Milano, Italy
    J Clin Oncol 21:1459-65. 2003
    ..To evaluate the effect of epirubicin on therapeutic response and survival in patients with indolent nonfollicular B-cell lymphomas (INFL) treated with pulsed high-dose chlorambucil...
  71. ncbi request reprint Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature
    Pellegrino Musto
    Unit of Haematology and Stem Cell Transplantation, CROB, Centro di Riferimento Oncologico di Basilicata, Strada Provinciale, 8, 85028, Rionero in Vulture PZ, Italy
    Leuk Res 31:1487-93. 2007
    ..However, some favourable trends or effects in favour of peg-filgrastim were observed. This was confirmed by a review of the published papers about this topic...
  72. ncbi request reprint Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
    Andrea Gallamini
    Struttura Complessa Ematologia Azienda Ospedaliera S Croce e Carle, Cuneo, Italy
    Blood 103:2474-9. 2004
    ..9% and 38.8%, respectively; group 3, 2 factors, with 5-year and 10-year OS of 32.9% and 18.0%, respectively; group 4, 3 or 4 factors, with a 5-year and 10-year OS of 18.3 and 12.6%, respectively (P< or =.0001; log-rank, 66.79)...
  73. ncbi request reprint Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma
    Luca Agnelli
    Centro di Genetica Molecolare ed Espressione Genica, Padiglione G Marcora, Fondazione IRCCS Ospedale Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy
    Haematologica 92:56-65. 2007
    ..The aim of this study was to provide a comprehensive analysis of the transcriptional features of Delta13 in MM...
  74. ncbi request reprint Melphalan and its role in the management of patients with multiple myeloma
    Patrizia Falco
    Azienda Ospedaliera San Giovanni Battista, Divisione di Ematologia dell Universita di Torino, Torino, Italy
    Expert Rev Anticancer Ther 7:945-57. 2007
    ....
  75. ncbi request reprint Pain syndromes in haematological malignancies: an overview
    Pasquale Niscola
    Hematology Unit, ASL Viterbo, Rome, Italy
    Hematol J 5:293-303. 2004
    ....
  76. ncbi request reprint Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses
    Sonia Fabris
    Laboratorio di Ematologia Sperimentale e Genetica Molecolare, UO Ematologia 1, Dipartimento di Scienze Mediche, Universita degli Studi di Milano, Ospedale Maggiore IRCCS, Milan, Italy
    Genes Chromosomes Cancer 42:117-27. 2005
    ..Our data suggest the importance of using combined molecular cytogenetic and gene expression approaches to detect genetic aberrations in MM...
  77. ncbi request reprint Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells
    Antonio Pellegrino
    Section of Medical Oncology, Hospital Vito Fazzi, Lecce
    Br J Haematol 129:248-56. 2005
    ..It is suggested that angiogenesis also favours MM progression through the release of CXC-chemokines...
  78. ncbi request reprint Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk
    Valentina Maggini
    Department of Biology, Pisa University, Pisa, Italy
    Leuk Res 32:988-90. 2008
    ..Individual genotypes of 128 patients affected by multiple myeloma and 245 healthy controls were determined and our results do not support any major role of NQO1 or GSTP1 polymorphisms in multiple myeloma pathogenesis...
  79. ncbi request reprint Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma
    Luca Agnelli
    Centro di Genetica Molecolare ed Espressione Genica, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy
    Br J Haematol 136:565-73. 2007
    ..These data reinforce the importance of combining molecular cytogenetics and gene expression profiling to define a genomic framework for the study of MM pathogenesis and clinical management...
  80. ncbi request reprint Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma
    Michela Mattioli
    Laboratorio di Ematologia Sperimentale e Genetica Molecolare and U O Ematologia 1, Dipartimento di Scienze Mediche, Universita degli Studi di Milano, Ospedale Maggiore IRCCS, Milano, Italy
    Oncogene 24:2461-73. 2005
    ....
  81. ncbi request reprint Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations
    Luca Agnelli
    UO Ematologia 2, Centro G Marcora, Ospedale Maggiore Policlinico IRCCS, Dipartimento Scienze Mediche, Universita degli Studi di Milano, Via Francesco Sforza 35, 20122 Milano, Italy
    J Clin Oncol 23:7296-306. 2005
    ..In this study, we provide a molecular characterization of the identified translocations/cyclins (TC) groups...
  82. ncbi request reprint Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukemia B-cells: anecdotal observation or pathogenetic hypothesis for the clinical outcome?
    Fortunato Morabito
    Haematologica 88:354-5. 2003
  83. ncbi request reprint IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia
    Davide Bagnara
    Department of Experimental Medicine, Human Anatomy Section, University of Genoa, Genoa, Italy
    Br J Haematol 133:50-8. 2006
    ..We conclude that antigen stimulation and somatic hypermutation may participate in disease progression through the selection and expansion of neoplastic subclone(s)...
  84. pmc B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens
    Elena Sabattini
    Haemolymphopathology Service, St Orsola Hospital, University of Bologna, Bologna, Italy
    J Clin Pathol 60:627-32. 2007
    ..The expression of zeta-associated protein 70 (ZAP70) is significantly associated with the more aggressive unmutated forms...
  85. doi request reprint Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis
    Giancarlo Pruneri
    Leuk Res 32:1628-32. 2008
  86. ncbi request reprint Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy
    Fortunato Morabito
    Centro Trapianti di Midollo Osseo, Dipartimento di Ematologia, Azienda Ospedaliera Bianchi Melacrino Morelli Via Melacrino, 89100 Reggio Calabria, Italy
    Leuk Lymphoma 43:1933-8. 2002
    ..In conclusion, the GISL definition of indolent disease is a reliable tool to design the appropriate therapeutic strategy in this histological setting...